Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
163
datasets available to search
ShareScore release 0.9.0
Dataset results
163 results for “Human papillomavirus (HPV)”
Human papillomavirus (HPV) detection in vaginal self-samples: evaluation of eNat® as an alternative suspension medium to ThinPrep®PreservCyt® for vaginal swabs
<p>Dataset 1: HPV positivity on cervical and vaginal self-samples with different HPV real-time PCR assays</p> <p>Dataset 2: hrHPV viral load in cervical and vaginal self-samples</p> <p>Datakey 1: HPV positivity on cervical and vaginal self-samples with different HPV real-time PCR assays</p> <p>Datakey 2: hrHPV viral load in cervical and vaginal self-samples</p>
Repurposing Type I-A CRISPR-Cas3 for a robust diagnosis of human papillomavirus (HPV)
<p>R-loop-triggered collateral single-stranded DNA (ssDNA) nuclease activity within Class 1 Type I CRISPR-Cas systems holds immense potential for nucleic acid detection. However, the hyperactive ssDNase activity of Cas3 introduces unwanted noise and false-positive results. In this study, we identified a novel Type I-A Cas3 variant derived from <em>Thermococcus siculi</em>, which remains in an auto-inhibited state until it is triggered by Cascade complex and R-loop formation. This Type I-A CRISPR-Cas3 system not only exhibits an expanded protospacer adjacent motif (PAM) recognition capability but also demonstrates remarkable intolerance towards mismatched sequences. Furthermore, it exhibits dual activation modes—responding to both DNA and RNA targets. The culmination of our research efforts has led to the development of the Hyper-Active-Verification Establishment (HAVE, 惠父). This innovation enables swift and precise <em>human papillomavirus</em> (HPV) diagnosis in clinical samples, providing a robust molecular diagnostic tool based on the Type I-A CRISPR-Cas3 system. Our findings contribute to understanding type I-A CRISPR-Cas3 system regulation and facilitate the creation of advanced diagnostic solutions with broad clinical applicability.</p>
A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects
ClinicalTrials.gov study NCT03438006. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls
ClinicalTrials.gov study NCT01381575. IPD Sharing: YES. Countries: 5. Publications: 4.
A Post-marketing Surveillance Study to Assess the Safety of Cervarix (GlaxoSmithKline [GSK] Biologicals' Human Papillomavirus [HPV] -16/18 Vaccine), When Administered According to the Approved Prescri
ClinicalTrials.gov study NCT03671369. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
ClinicalTrials.gov study NCT02291055. IPD Sharing: NO. Countries: 1. Publications: 0.
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects
ClinicalTrials.gov study NCT00947115. IPD Sharing: YES. Countries: 2. Publications: 1.
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
ClinicalTrials.gov study NCT00604175. IPD Sharing: Not stated. Countries: 4. Publications: 8.
Innovative Tool to Increase Completion of Human Papillomavirus (HPV) Vaccine Series
ClinicalTrials.gov study NCT01343485. IPD Sharing: Not stated. Countries: 1. Publications: 8.
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.
ClinicalTrials.gov study NCT00877877. IPD Sharing: YES. Countries: 5. Publications: 2.
Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer
ClinicalTrials.gov study NCT02908477. IPD Sharing: NO. Countries: 1. Publications: 2.
Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study
ClinicalTrials.gov study NCT03629886. IPD Sharing: YES. Countries: 1. Publications: 1.
Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India
ClinicalTrials.gov study NCT00923702. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Self-sampling for Human Papillomavirus (HPV) Among Patients Receiving Colposcopy
ClinicalTrials.gov study NCT04585243. IPD Sharing: NO. Countries: 1. Publications: 4.
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
ClinicalTrials.gov study NCT00423046. IPD Sharing: YES. Countries: 1. Publications: 8.
Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects
ClinicalTrials.gov study NCT00652938. IPD Sharing: YES. Countries: 2. Publications: 2.
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
ClinicalTrials.gov study NCT03158220. IPD Sharing: YES. Countries: 6. Publications: 1.
Vax Facts Human Papillomavirus (HPV): Study of a Computer-based Tailoring System and Mothers' Intentions to Vaccinate Their Daughters Against HPV
ClinicalTrials.gov study NCT01143142. IPD Sharing: Not stated. Countries: 1. Publications: 8.
Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine
ClinicalTrials.gov study NCT00316693. IPD Sharing: YES. Countries: 1. Publications: 8.
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.
ClinicalTrials.gov study NCT00481767. IPD Sharing: YES. Countries: 2. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.